血管内皮生长因子对神经细胞的保护作用及机制

目的:探讨血管内皮生长因子(VEGF)对体外培养的神经元的保护作用及机制。方法:体外培养大鼠皮质神经元细胞,建立神经细胞缺氧缺糖/再灌注损伤模型(OGSD),在加入VEGF基础上,加入VEGFR-2/Flk-1受体抑制剂SU1498;检测(1)观察细胞形态学变化;(2)细胞活力;(3)线粒体跨膜电位;(4)凋亡相关蛋白Bc1-2和Bax表达。结果:(1)OGSD组、VEGF164 SU1498组细胞损害重,VEGF组细胞损害轻(P<0.05);(2)OGSD组、VEGF164 SU1498组细胞活力下降明显(P<0.05),而VEGF组与正常组无明显区别;(3)OGSD组、VEGF164 SU1498组线粒体跨膜电位不稳定(P<0.05),VEGF组线粒体跨膜电位稳定;(4)OGSD组、VEGF164 SU1498组Bcl-2、Bax蛋白表达均增多,VEGF组Bcl-2蛋白表达增多最明显(P<0.01),而Bax蛋白表达增多最不明显(P<0.01)。结论:VEGF对神经元起直接的保护作用,并通过与VEGFR-2受体结合减少了缺血、缺氧下培养的体外神经元细胞的凋亡。     

血管内皮生长因子与血管新生

冠心病康复的关键疑点——运动是否可以促进冠状动脉侧支循环形成一直是国际上研究的焦点。血管内皮生长因子(vascular endothelial growth factor，VEGF)在血管新生中的作用就是焦点中的焦点。     

外源性血管内皮生长因子对短暂性脑缺血的保护作用

目的：研究血管内皮生长因子（VEGF）在脑缺血再灌注后的保护作用。方法：用大脑中动脉闭塞（MCAO）模型，结合TTC染色和计算机图象分析测量梗死体积，观察VEGF对缺血性脑梗死体积的影响。结果：侧脑室注射VEGF与对照比较能减少梗死体积。结论：侧脑室注射VEGF能减轻脑缺血再灌注后的脑损伤，提示VEGF可能对缺血的脑组织有保护作用。     

血管内皮生长因子的研究进展

血管内皮生长因子(VEGF)是血管生成的主要调控因子,特异性地作用于血管内皮细胞。VEGF受体特异性地分布于血管内皮细胞,促进内皮细胞的增殖和迁移。本文就VEGF的分子特征、VEGF受体及信号转导、VEGF及受体的表达调控作一综述。     

血管内皮生长因子的研究进展

血管内皮生长因子（VEGF）是血管生成的主要调控因子，特异性地作用于血管内皮细胞。VEGF受体特异性地分布于血管内皮细胞，促进内皮细胞的增殖和迁移。本文就VEGF的分子特征、VEGF受体及信号转导、VEGF及受体的表达调控作一综述。     

外源性血管内皮生长因子对短暂性脑缺血的保护作用

目的研究血管内皮生长因子(VEGF)在脑缺血再灌注后的保护作用。方法用大脑中动脉闭塞(MCAO)模型,结合TTC染色和计算机图象分析测量梗死体积,观察VEGF对缺血性脑梗死体积的影响。结果侧脑室注射VEGF与对照比较能减少梗死体积。结论侧脑室注射VEGF能减轻脑缺血再灌注后的脑损伤,提示VEGF可能对缺血的脑组织有保护作用。     

血管内皮生长因子及其基因对缺血脑组织保护作用与Bax和Bcl-2表达的相关性

目的：探讨血管内皮生长因子(vascular endothelial growth factor．VEGF)基因对缺血脑组织脑梗死神经细胞的保护作用与Bax和Bcl-2水平的关系，以及VEGF作用的机制。方法：用线拴法制成Wistar大鼠大脑中动脉永久性闭塞模型，将VEGF-真核表达质粒(pUCCAGGS／hVEGF165)经颅骨注入到缺血区。术后7d断头取脑，用反转录PCR(RT-PCR)检测VEGF mRNA的表达强度，用免疫组织化学方法检测Bax，Bcl-2和VEGF的表达水平。结果：与对照组相比，治疗组VEGF mRNA的表达增强，VEGF表达增高[(32．50&;#177;2．45)个／高倍视野比(3．33&;#177;1．03)个／高倍视野，t=334．821．P&;lt;0．01]，Bax表达减弱【(4．11&;#177;0，41)个／高倍视野，t=9，168，P&;lt;0．01】，Bcl-2表达增强【(7．94&;#177;0．49)个／高倍视野，r=5．335，P&;lt;0．01】。结论：VEGFm基因可以转化到缺血脑组织中并表达VEGF mRNA和VEGF，后者可能通过抑制Bax和增强Bcl-2的表达而保护神经细胞。     

血管内皮生长因子受体与恶性肿瘤

肿瘤的生长和转移依赖于新生血管的形成，已知有多种细胞因子、生长因子及其受体参与了血管形成的调控，其中血管内皮生长因子(VEGF)可能是最关键的刺激因子。而VEGF的生物学效应是通过其特异性的膜受体介导实现的，迄今发现VEGF有三种受体：VEGFR—1、VEGFR—2、VEGFR—3。它们在血管生成中的调节作用和以VEGFR为靶点的抗肿瘤治疗研究，是当前研究的热点。本文主要综述这方面的进展。     

血管内皮生长因子与缺血性脑血管病

本文旨在通过对血管内皮生长因子(vascular endothelial growth factor，VEGF)与缺血性脑血管病的综述，阐明VEGF对缺血性脑血管的保护作用及应用前景。     

血管内皮生长因子受体与恶性肿瘤

肿瘤的生长和转移依赖于新生血管的形成 ,已知有多种细胞因子、生长因子及其受体参与了血管形成的调控 ,其中血管内皮生长因子 (VEGF)可能是最关键的刺激因子。而VEGF的生物学效应是通过其特异性的膜受体介导实现的 ,迄今发现VEGF有三种受体 :VEGFR 1、VEGFR 2、VEGFR 3。它们在血管生成中的调节作用和以VEGFR为靶点的抗肿瘤治疗研究 ,是当前研究的热点。本文主要综述这方面的进展     

血管内皮生长因子与糖尿病肾病的相关性研究

目的探讨血管内皮生长因子(VEGF)与2型糖尿病肾病的关系。方法采用ELISA法测定2型糖尿病患者216例(其中单纯2型糖尿病患者112例，糖尿病肾病患者104．例)和正常对照组98例血清中的VEGF，并分析其与2型糖尿病并发肾病的关系。结果糖尿病肾病患者血清VEGF水平显著高于单纯2型糖尿病组和正常对照组。血清VEGF与收缩压、糖化血红蛋白、尿白蛋白排泄率呈显著正相关，与年龄、性别、病程、体重指数、血脂等无显著相关性。结论血清VEGF与2型糖尿病肾病密切相关，其浓度的检测对监测2型糖尿病肾病的发生、发展有重要的临床意义。     

血管内皮生长因子与糖尿病肾病关系探讨

目的 探讨血管内皮生长因子(VEGF)与2型糖尿病肾病的关系.方法 检测2型糖尿病患者122例和正常对照组40例血清VEGF水平,按尿微量白蛋白排泄率(UAER)水平分组比较检测结果.结果 糖尿病各组患者血清VEGF水平较正常对照组显著升高,与糖化血红蛋白(HbA1C)、病程、UAER呈显著正相关(P＜0.01).结论 血清VEGF与2型糖尿病肾病密切相关,其浓度的测定对判断2型糖尿病肾病的发生、发展有重要的临床意义.     

血管内皮细胞生长因子与缺血性脑血管病

血管内皮细胞生长因子( vascular endothelial growth factor,VEGF)是迄今为止已知的最强的促血管生长因子,其由多种正常细胞产生和分泌,特异性作用于存在 VEGF受体即 flt-l(VEGFR-1)或 KDR(VEGFR-2)的血管内皮细胞( VEC)而实现其生物学效应.除人们所熟知的可以增加血管通透性,促进血管生成,维持血管功能,修复损伤后血管的功能外,更有研究表明其对神经细胞有直接保护作用并可促进神经元的生成.缺氧为 VEGF/VEGFR表达的最强调节因素.许多实验都证实了脑缺血过程中均伴有 VEGF及其受体的表达,与缺血性脑血管病的发生发展密切相关.目前 VEGF作为一种功能强大且能产生多种效应的细胞因子因其潜在的治疗前景引起国内外的广泛关注.     

Vascular endothelial growth factor and oxidative damage in cancer

OBJECTIVES: VEGF may be an indicator for the angiogenic potential of a tumor and stimulates NO which plays complex roles in cancer. In our study, we investigated the levels of MDA, NO and VEGF in the plasma of various types cancer patients (untreated, yet). DESIGN AND METHODS: The level of VEGF was determined by using ELISA. Plasma MDA, NO and VEGF levels were measured in 45 patients with various cancer types and in 21 healthy subjects. RESULTS: Plasma MDA and VEGF levels were significantly higher than those of the healthy subjects (p < 0,0001). NO levels of the patients were significantly lower vs. the healthy subjects (p < 0,001). CONCLUSIONS: Increased plasma VEGF and MDA concentrations and decreased plasma NO levels have been found in patients with various types of human cancer. Howewer, the prognostic and clinical significance of plasma VEGF in cancer patients is unknown.     

Vascular endothelial growth factor in thyroid cyst fluids

BACKGROUND: The pathogenesis of cystic thyroid nodules is incompletely understood. Based on the assumption that vascular endothelial growth factor (VEGF) may play an important role in the pathogenesis of thyroid cyst fluid, we investigated the VEGF concentration in cyst fluids of thyroid lesions. DESIGN: Cyst fluids from 24 patients (age 31-84 years) were obtained using ultrasound-guided fine-needle aspiration. The patients' cystic thyroid nodules were of different origins. METHODS: Thyroid and cyst volumes were determined using high-resolution ultrasonography. VEGF concentrations were determined using a solid-phase enzyme-linked immunosorbent assay (ELISA). RESULTS: Differing elevated VEGF concentrations were demonstrated in cyst fluids of thyroid nodules of varied origins. The VEGF concentration in cyst fluid of patients with adenomatous goiter was significantly higher (P < 0.05) than that in thyroid nodules with cystic degeneration. The highest level of VEGF was found in bloody cyst fluid when compared with levels in other cyst fluids (P < 0.05). Interestingly, there was significant correlation (P < 0.01) between thyroid volume and VEGF concentration in cyst fluid, but no significant correlation (P = 0.20) between cyst volume and VEGF concentration. CONCLUSION: Significantly increased VEGF concentrations were found in bloody cyst fluid and in cyst fluid of thyroid adenomatous goiter, compared with VEGF concentrations in degenerative thyroid cysts. Our results suggest that VEGF may play an important role in the pathogenesis of thyroid cyst fluid.     

血管内皮生长因子与放射性视网膜病变新生血管的形成

目的:放射性视网膜病变作为头、颈部肿瘤放射治疗的一种眼部并发症,国内外的报道不多,其发病机制尚未完全明确,因此归纳总结放射性视网膜病变的发病机制以为临床治疗提供依据。资料来源:应用计算机检索Pubmed数据库1990-01/2006-06期间有关放射性视网膜病变的文章,检索词“VEGF,Radiation Retinopathy,New Blood Vessels”,限定文章语言种类为English。同时计算机检索中国期刊全文数据库1990-01/2006-06期间的相关文章,检索词“血管内皮生长因子,放射性视网膜病变,新生血管生成”,限定文章语言种类为中文。资料选择:对资料进行初审,取符合研究要求的有关文章找全文。资料提炼:共收集到60篇有关血管内皮生长因子及放射性视网膜病变的文章,其中45篇为血管内皮生长因子在各系统器官中的作用,涉及糖尿病视网膜病变,放射性视网膜病变等方面;其中15篇为放射性视网膜病变文章,涉及病例个案报道,临床观察等方面。资料综合:①放射性视网膜病变眼底视网膜新生血管形成是其特点性病变。血管内皮生长因子近年来被确定为对新生血管性疾病发展过程有重要影响的细胞因子。②血管内皮生长因子可诱导视网膜下新生血管的形成。缺氧启动了血管新生的过程。③发病机制考虑为放射线诱导的DNA损伤使内皮细胞在有丝分裂过程中死亡,当正常分裂的细胞数量难以补偿丢失的细胞时,血管内皮连续性破坏,功能障碍。结论:目前放射性视网膜病变的发病机制仍有争议,但眼底新生血管出现是其重要的临床表现。血管内皮生长因子的表达高低与新生血管形成有关。     

血管内皮细胞生长因子对人脐静脉间充质干细胞生长增殖的影响

背景:在体外构建组织工程材料的过程中,快速获得足够数量且纯度高的种子细胞极为重要,但目前人脐静脉间充质干细胞原代培养的增殖率仍较低.目的:观察血管内皮细胞生长因子对人脐静脉间充质干细胞原代生长、增殖的影响.设计、时间及地点:细胞学体外观察,于2008 03/07在辽宁医学院解剖学实验室完成.材料:正常健康产妇顺产或剖宫产的新生儿脐带20条,由锦州市凌河区妇幼保健院及辽宁医学院附属第一医院提供.方法:采用胶原酶消化法分离人脐静脉间充质干细胞,以1×105L-1的密度接种于24孔培养板,设立2组,实验组加入150 g/L 血管内皮细胞生长因子,对照组不加入任何细胞因子.主要观察指标:观察细胞形态变化,MTT法检测细胞生长曲线,免疫细胞化学法鉴定细胞CD166的表达.结果:接种后6 h细胞开始贴壁,48 h后细胞完全贴壁生长,出现呈椭圆形、多角形的内皮细胞,以及呈梭形的成纤维样细胞,有的形成漩涡状生长集落;原代培养1周后细胞以梭形为主;传代后24 h细胞基本完成贴壁,48 h细胞开始分裂增殖,5～7 d可见多核的成纤维样细胞贴壁,呈长杆状、三角形、梭形等.与对照组比较,实验组细胞生长状态较好,增殖较快,单位时间内获得的细胞数量明显增加(t=2.235,P＜0.05),CD166阳性细胞率显著升高(t=-1.638,P＜0.01).结论:血管内皮细胞生长因子可促进入脐静脉间充质干细胞贴壁,且更有利于间充质干细胞的增殖和纯化.     

血管内皮生长因子及其对成骨的影响

目的综述有关血管内皮细胞生长因子(vascular endothelial growth facrot,VEGF)的实验结果及其对成骨的影响,明确VEGF是否能促进骨的形成.资料来源资料来源于http//www.ncbi.nlm.nih.gov/pubmed和http//www.zglckf.com数据库等相关网站,采取电子数据检索方式获得.资料选择选择有关VEGF的文章以及VEGF影响成骨的文章近30篇.不考虑文章中是否应用随机设计、盲法.数据提炼这些研究证实了VEGF和VEGF受体的结构、生物学特性、表达.提示VEGF通过促进新生血管的形成、加快骨转换和阻止软骨细胞凋亡在软骨内成骨中扮演重要角色.膜内成骨中,在无软骨出现的情况下,成骨细胞产生、应答VEGF.VEGF激活、趋化破骨细胞,同时趋化、分化成骨细胞和促进基质的矿化.目前关于局部单纯应用外源性VEGF能否促进成骨仍有争论.但在某些情况如局部缺血环境下,增加局部VEGF可促进成骨.资料综合与对照组相比,VEGF能通过对软骨内成骨、膜内成骨的影响促进骨的发生、形成和改建.结论局部VEGF治疗的优势在于其既可刺激血管形成又可促进骨的形成和改建.如果最终能应用VEGF的这些特性治疗缺血性骨坏死、骨缺损、骨不连等疾病,将发现一条新的治疗途径.     

Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients

OBJECTIVE: Vascular endothelial growth factor (VEGF) promotes normal and pathological angiogenesis. VEGF is a chemotactic factor for macrophages and vascular smooth muscle cells, and induces synthesis of metalloproteinases and adhesion molecules. VEGF expression is regulated by hypoxia, cytokines, oncogenes, and oxidized low-density lipoprotein (LDL). The purpose of this study was to determine the relationship between levels of lipid parameters and VEGF, to investigate whether pravastatin treatment influences VEGF serum concentrations, and to examine the relationship between VEGF and the variations in post-treatment lipid and inflammatory parameters. MATERIAL AND METHODS: Eighteen patients aged 48+/-6.8 years with total cholesterol (TC) >6.1 mmol/L comprised the hypercholesterolemic group. The controls included 12 individuals aged 50+/-7.4 years with TC <5.1 mmol/L. TC, high-density lipoprotein cholesterol (HDLC), triglycerides, LDLC, C-reactive protein (CRP), and VEGF were determined in both groups at baseline, and in the hypercholesterolemic group after 4 months of treatment with 20 mg/day pravastatin. RESULTS: A significant correlation was observed between concentrations of VEGF and TC, LDLC and TG, and a significant difference in VEGF concentration was observed between the control group (mean 142 ng/L) and the hypercholesterolemic group (mean 272.9 ng/L). A significant decrease was observed in TC (14.7 %), LDLC (21.5 %), CRP (22.7 %), and VEGF (14.8 %) after 4 months of treatment with pravastatin. CONCLUSIONS: A relationship was found between serum levels of VEGF and most atherogenic lipoproteins. In patients with hypercholesterolemia treated with pravastatin, a reduction in VEGF and CRP was seen in addition to lipid decreases.     

Vascular endothelial growth factor serum concentrations in hypercholesterolemic patients

Objective. Vascular endothelial growth factor (VEGF) promotes normal and pathological angiogenesis. VEGF is a chemotactic factor for macrophages and vascular smooth muscle cells, and induces synthesis of metalloproteinases and adhesion molecules. VEGF expression is regulated by hypoxia, cytokines, oncogenes, and oxidized low‐density lipoprotein (LDL). The purpose of this study was to determine the relationship between levels of lipid parameters and VEGF, to investigate whether pravastatin treatment influences VEGF serum concentrations, and to examine the relationship between VEGF and the variations in post‐treatment lipid and inflammatory parameters. Material and methods. Eighteen patients aged 48±6.8 years with total cholesterol (TC) >6.1?mmol/L comprised the hypercholesterolemic group. The controls included 12 individuals aged 50±7.4 years with TC <5.1?mmol/L. TC, high‐density lipoprotein cholesterol (HDLC), triglycerides, LDLC, C‐reactive protein (CRP), and VEGF were determined in both groups at baseline, and in the hypercholesterolemic group after 4 months of treatment with 20?mg/day pravastatin. Results. A significant correlation was observed between concentrations of VEGF and TC, LDLC and TG, and a significant difference in VEGF concentration was observed between the control group (mean 142?ng/L) and the hypercholesterolemic group (mean 272.9?ng/L). A significant decrease was observed in TC (14.7 %), LDLC (21.5 %), CRP (22.7 %), and VEGF (14.8 %) after 4 months of treatment with pravastatin. Conclusions. A relationship was found between serum levels of VEGF and most atherogenic lipoproteins. In patients with hypercholesterolemia treated with pravastatin, a reduction in VEGF and CRP was seen in addition to lipid decreases.